BioMarin Pharmaceutical Inc. (BMRN) Ownership
BMRN ownership summary
as of October 18, 2026- Institutions
- 103.3% of shares outstanding
- Insiders
- 0.34% of shares outstanding
- Shares outstanding
- 193.6M
- Float
- 192.6M shares available to trade
- Short interest
- 5.97% 11.5M shares short
- Days to cover
- 5.73 short interest up 14.4% vs prior month
- Institutions 103.32%
- Insiders 0.34%
BMRN top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 10.56% | 20.4M | $1.12B | +626,911 (+3.2%) | June 30, 2026 |
| 2 | Dodge & Cox | 7.67% | 14.8M | $811.7M | +283,171 (+1.9%) | June 30, 2026 |
| 3 | PRIMECAP Management Company | 7.33% | 14.2M | $775.9M | −3,822 (−0.0%) | June 30, 2026 |
| 4 | Vanguard Capital Management, LLC | 4.52% | 8.7M | $478.1M | +100,469 (+1.2%) | June 30, 2026 |
| 5 | Vanguard Portfolio Management, LLC | 4.47% | 8.6M | $472.9M | +350,203 (+4.2%) | June 30, 2026 |
| 6 | NORGES BANK | 4.24% | 8.2M | $448.8M | +676,874 (+9.0%) | June 30, 2026 |
| 7 | State Street Corp | 4.03% | 7.8M | $426.6M | +505,880 (+6.9%) | June 30, 2026 |
| 8 | Viking Global Investors LP | 3.93% | 7.6M | $416.5M | +554,486 (+7.9%) | June 30, 2026 |
| 9 | Vestal Point Capital LP | 3.11% | 6.0M | $329.4M | +2.5M (+68.5%) | June 30, 2026 |
| 10 | AQR Capital Management LLC | 2.94% | 5.7M | $311.7M | −2.0M (−25.8%) | June 30, 2026 |
| 11 | FMR Inc | 2.49% | 4.8M | $263.7M | +1.3M (+35.2%) | June 30, 2026 |
| 12 | Dimensional Fund Advisors, Inc. | 2.11% | 4.1M | $222.9M | +272,784 (+7.2%) | June 30, 2026 |
| 13 | Geode Capital Management, LLC | 2.02% | 3.9M | $213.9M | +92,353 (+2.4%) | June 30, 2026 |
| 14 | Assenagon Asset Management SA | 1.82% | 3.5M | $192.7M | +1.6M (+83.5%) | June 30, 2026 |
| 15 | Capital Research Global Investors | 1.81% | 3.5M | $191.6M | +13,001 (+0.4%) | June 30, 2026 |
| 16 | Deep Track Capital, LP | 1.71% | 3.3M | $180.9M | +2.2M (+187.6%) | June 30, 2026 |
| 17 | Millennium Management LLC | 1.07% | 2.1M | $113.3M | −938,492 (−31.2%) | June 30, 2026 |
| 18 | Charles Schwab Investment Management Inc | 0.83% | 1.6M | $88.4M | +28,337 (+1.8%) | June 30, 2026 |
| 19 | First Trust Advisors L.P. | 0.83% | 1.6M | $87.8M | −66,218 (−4.0%) | June 30, 2026 |
| 20 | Northern Trust Corp | 0.80% | 1.6M | $85.2M | −28,280 (−1.8%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 11.0M shares and 5 cut 3.0M.
BMRN top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Dodge & Cox Stock I | 5.05% | 9.8M | $534.2M | — | June 30, 2026 |
| 2 | iShares Core S&P Mid-Cap ETF | 3.56% | 6.9M | $377.0M | −2,460 (−0.0%) | September 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 3.18% | 6.2M | $336.5M | −7,621 (−0.1%) | August 31, 2026 |
| 4 | Vanguard Capital Opportunity Inv | 2.67% | 5.2M | $282.6M | +72,500 (+1.4%) | June 30, 2026 |
| 5 | Vanguard PRIMECAP Inv | 2.57% | 5.0M | $271.7M | −201,000 (−3.9%) | June 30, 2026 |
| 6 | Vanguard Small Cap Index | 2.25% | 4.4M | $238.3M | −90,053 (−2.0%) | September 30, 2026 |
| 7 | Fidelity Contrafund | 1.47% | 2.8M | $155.1M | −926 (−0.0%) | August 31, 2026 |
| 8 | American Funds Cptl Wld Gr&Inc A | 1.33% | 2.6M | $140.9M | — | September 30, 2026 |
| 9 | R-co Valor C EUR | 1.30% | 2.5M | $137.9M | −593,756 (−19.1%) | August 31, 2026 |
| 10 | Vanguard MStar Small Cap Growth Indx Inv | 1.25% | 2.4M | $132.5M | −129,385 (−5.1%) | September 30, 2026 |
| 11 | State Street® SPDR® S&P® Biotech ETF | 1.19% | 2.3M | $126.3M | −43,950 (−1.9%) | September 30, 2026 |
| 12 | First Trust NYSE Arca Biotech ETF | 0.79% | 1.5M | $83.7M | — | September 30, 2026 |
| 13 | iShares Biotechnology ETF | 0.77% | 1.5M | $81.5M | −11,296 (−0.8%) | September 30, 2026 |
| 14 | State Street® SPDR® S&P MIDCAP 400® ETF | 0.74% | 1.4M | $78.3M | +17,760 (+1.3%) | September 30, 2026 |
| 15 | PRIMECAP Odyssey Aggressive Growth | 0.73% | 1.4M | $77.5M | +36,743 (+2.7%) | June 30, 2026 |
| 16 | DNB Global A | 0.54% | 1.0M | $57.3M | +10,428 (+1.0%) | August 31, 2026 |
| 17 | State Street SPDR Port S&P 400 Md CpETF | 0.53% | 1.0M | $56.0M | −1,440 (−0.1%) | September 30, 2026 |
| 18 | PRIMECAP Odyssey Growth | 0.51% | 979K | $53.5M | +14,300 (+1.5%) | June 30, 2026 |
| 19 | Dodge & Cox Balanced I | 0.49% | 955K | $52.2M | — | June 30, 2026 |
| 20 | Fidelity Extended Market Index | 0.49% | 943K | $51.6M | −11,953 (−1.3%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
BMRN insider transactions
latest 4| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-11 | Charles Greg Guyer | Sell | $60.46 | 16,486 | $996,744 |
| 2026-02-26 | Gregory R Friberg | Sell | $60.38 | 6,326 | $381,964 |
| 2025-05-20 | Erin Burkhart | Sell | $59.31 | 1,786 | $105,928 |
| 2025-05-02 | Cristin Hubbard | Sell | $64.92 | 273 | $17,723 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
BMRN shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns BMRN
Institutional investors own 103.3% of BioMarin Pharmaceutical's shares and insiders 0.34%. The largest holder is BlackRock Inc with 10.56% of the shares (20.4M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 5 reduced their stake in the latest filings. Short interest is 5.97% of the float, or 5.73 days of average trading volume. The share count rose 33.2% since 2014.
Related: BMRN analyst forecast, BMRN key metrics. See the BMRN stock overview for the latest quote and news.
BMRN ownership FAQ
Who owns the most BioMarin Pharmaceutical stock?
The largest shareholders of BioMarin Pharmaceutical are BlackRock Inc (10.56%), Dodge & Cox (7.67%), PRIMECAP Management Company (7.33%), Vanguard Capital Management, LLC (4.52%), Vanguard Portfolio Management, LLC (4.47%).
What percentage of BioMarin Pharmaceutical is owned by institutions?
Institutions hold 103.3% of BioMarin Pharmaceutical's shares outstanding; insiders hold 0.34%.
Which funds own BioMarin Pharmaceutical?
The largest fund holders of BioMarin Pharmaceutical are Dodge & Cox Stock I (5.05%), iShares Core S&P Mid-Cap ETF (3.56%), Vanguard MStar Total Stk Mkt Idx Invest (3.18%), Vanguard Capital Opportunity Inv (2.67%), Vanguard PRIMECAP Inv (2.57%).
What is BioMarin Pharmaceutical's short interest?
11.5M shares of BioMarin Pharmaceutical were sold short, 5.97% of the float; at the average daily volume it would take 5.73 days to cover.
Are insiders buying or selling BioMarin Pharmaceutical?
Of the latest 4 reported insider transactions in BioMarin Pharmaceutical (since May 2, 2025), 0 were purchases and 4 were sales.
How many shares of BioMarin Pharmaceutical are outstanding?
BioMarin Pharmaceutical has 193.6M shares outstanding, of which 192.6M are in the public float.